Abstract
The incidentally discovered, clinically-localized, small renal mass (clinical stage T1aN0M0, ≤4cm) is the most commonly diagnosed entity in Renal Cell Carcinoma (RCC) – now accounting for at least 40% of newly diagnosed renal tumors. Given the above argument, Active Surveillance (AS) has emerged as a viable management strategy for SRM. This review will examine and discuss the existing literature regarding selection criteria for AS.
AS of clinical T1a renal masses is emerging as a safe and effective management strategy in selected patients, yet appropriate patient selection and counseling remains an area of great interest. Long-term clinical outcomes are just beginning to be reported, thus much of the supporting evidence on AS and patient selection is based on retrospective data of heterogeneous quality. Nevertheless, there are certain conclusions that can be drawn, despite these current limitations. Appropriate selection of candidates should include a comprehensive evaluation of competing health risks, tumor characteristics, and patient preferences.
Keywords: Small renal mass, renal cell carcinoma, carcinoma, active surveillance, tumor characteristics, malignant potential.
Anti-Cancer Agents in Medicinal Chemistry
Title:Selecting Patients with Small Renal Masses for Active Surveillance
Volume: 18 Issue: 7
Author(s): Michael H. Johnson, Mohamad E. Allaf and Phillip M. Pierorazio*
Affiliation:
- The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins Hospital, Baltimore, 21287 MD,United States
Keywords: Small renal mass, renal cell carcinoma, carcinoma, active surveillance, tumor characteristics, malignant potential.
Abstract: The incidentally discovered, clinically-localized, small renal mass (clinical stage T1aN0M0, ≤4cm) is the most commonly diagnosed entity in Renal Cell Carcinoma (RCC) – now accounting for at least 40% of newly diagnosed renal tumors. Given the above argument, Active Surveillance (AS) has emerged as a viable management strategy for SRM. This review will examine and discuss the existing literature regarding selection criteria for AS.
AS of clinical T1a renal masses is emerging as a safe and effective management strategy in selected patients, yet appropriate patient selection and counseling remains an area of great interest. Long-term clinical outcomes are just beginning to be reported, thus much of the supporting evidence on AS and patient selection is based on retrospective data of heterogeneous quality. Nevertheless, there are certain conclusions that can be drawn, despite these current limitations. Appropriate selection of candidates should include a comprehensive evaluation of competing health risks, tumor characteristics, and patient preferences.
Export Options
About this article
Cite this article as:
Johnson H. Michael , Allaf E. Mohamad and Pierorazio M. Phillip*, Selecting Patients with Small Renal Masses for Active Surveillance, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (7) . https://dx.doi.org/10.2174/1871520617666171113152225
DOI https://dx.doi.org/10.2174/1871520617666171113152225 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibitors for Metastasis Development
Recent Patents on Anti-Cancer Drug Discovery Folate Receptor Targeted Liposomes Encapsulating Anti-Cancer Drugs
Current Pharmaceutical Biotechnology Endoglin Silencing has Significant Antitumor Effect on Murine Mammary Adenocarcinoma Mediated by Vascular Targeted Effect
Current Gene Therapy Perinatal Management of Fetal Tumors
Current Pediatric Reviews Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer
Current Protein & Peptide Science Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms
Current Drug Targets Protein Kinase C Isozymes as Potential Targets for Anticancer Therapy
Current Cancer Drug Targets MicroRNA-dependent Regulation of Telomere Maintenance Mechanisms: A Field as Much Unexplored as Potentially Promising
Current Pharmaceutical Design Tools For Decision-Making In Older Cancer Patients. Role Of The Comprehensive Geriatric Assessment
Anti-Cancer Agents in Medicinal Chemistry CD147 Interacts with NDUFS6 in Regulating Mitochondrial Complex I Activity and the Mitochondrial Apoptotic Pathway in Human Malignant Melanoma Cells
Current Molecular Medicine Nucleic Acid Aptamers Based on the G-Quadruplex Structure: Therapeutic and Diagnostic Potential
Current Medicinal Chemistry Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy
Current Drug Targets Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research The Promotional Effect of Mesenchymal Stem Cell Homing on Bone Tissue Regeneration
Current Stem Cell Research & Therapy Chemistry and Pharmacological Properties of Some Natural and Synthetic Antioxidants for Heavy Metal Toxicity
Current Medicinal Chemistry Current Molecularly Targeting Therapies in NSCLC and Melanoma
Anti-Cancer Agents in Medicinal Chemistry Viral Origins of Human Cancer
Current Medicinal Chemistry Pharmacology of Rhein and Advancement in the Synthesis of Its Derivatives
Current Traditional Medicine MicroRNA-155 Functions as a Negative Regulator of RhoA Signaling in TGF-β-induced Endothelial to Mesenchymal Transition
MicroRNA MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential
Current Genomics